Trial Profile
Phase I/II Study of Polyphenon E in Addition to Erlotinib in Advanced Non Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Polyphenon E (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 30 Dec 2014 Protocol has been amended to change in primary outcome, inclusion criteria and treatment arms.
- 30 Dec 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 26 Aug 2011 Planned End Date changed from 1 Dec 2011 to 1 Aug 2012 as reported by ClinicalTrials.gov record.